Results 161 to 170 of about 3,353 (184)
Some of the next articles are maybe not open access.
Rapid detection of imipenem/relebactam susceptibility/resistance in Pseudomonas aeruginosa
Diagnostic Microbiology and Infectious DiseaseImipenem-relebactam (IPR) has been reported to exhibit a good activity against non-metallo-ß-lactamase carbapenem-resistant Pseudomonas aeruginosa (CRPA), and the rapid detection of susceptibility/resistance to this new therapeutic alternative may be crucial.
Maxime Bouvier +3 more
openaire +2 more sources
Imipenem-cilastatin and imipenem-relebactam
2017The carbapenems are a group of bicyclic beta-lactam compounds with a common carbapenem nucleus. Imipenem (N-formimidoyl-thienamycin: C12H17N3O4S; average molecular weight: 299.3460) is one of these, and it has substantial activity against both aerobic and anaerobic bacteria, including many (but not all) beta-lactamase-producing strains.
Hayashi, Yoshiro, Paterson, David L.
openaire +2 more sources
Imipenem/cilastatina/relebactam en infecciones por bacterias gramnegativas
Panorama Actual del MedicamentoRelebactam es un nuevo inhibidor de betalactamasas con estructura no betalactámica, con capacidad para inhibir betalactamasas de tipo A y C, pero no B y D. Sin actividad antibacteriana significativa, la función de relebactam en la combinación con imipenem y cilastatina consiste en restituir la actividad bactericida de imipenem cuando ésta se ve ...
openaire +1 more source